Predicted to enable enzyme inhibitor activity and myosin phosphatase regulator activity. Predicted to be involved in several processes, including establishment of endothelial barrier; positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis; and regulation of protein dephosphorylation. Predicted to be located in several cellular components, including nuclear speck; perinuclear region of cytoplasm; and plasma membrane. Predicted to be active in cytoplasm. Orthologous to human PPP1R16B (protein phosphatase 1 regulatory subunit 16B); INTERACTS WITH 17beta-estradiol; 17beta-estradiol 3-benzoate; 2,3,7,8-tetrachlorodibenzodioxine.
[Estradiol co-treated with TGFB1 protein] results in decreased expression of PPP1R16B mRNA, [Progesterone co-treated with Estradiol] results in decreased expression of PPP1R16B mRNA
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PPP1R16B mRNA
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PPP1R16B mRNA
[Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in decreased expression of PPP1R16B mRNA, [Air Pollutants results in increased abundance of Ozone] which results in decreased expression of PPP1R16B mRNA
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PPP1R16B mRNA
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PPP1R16B mRNA